Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Avadel Pharmaceuticals ( (AVDL) ).
On August 29, 2025, Avadel Pharmaceuticals entered into an exclusive global license agreement with XWPharma Ltd. to develop and commercialize valiloxybate, a GABAB receptor agonist, for sleep disorders such as narcolepsy and idiopathic hypersomnia. This agreement, excluding mainland China, Hong Kong, and Macau, involves a $20 million upfront payment to XWPharma, with potential milestone and royalty payments based on sales achievements. The development of valiloxybate is expected to enhance Avadel’s sleep medicine portfolio and leverage its existing infrastructure for efficient clinical and regulatory advancement.
The most recent analyst rating on (AVDL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
Avadel Pharmaceuticals is on a positive trajectory with strong revenue growth and operational improvements. The bullish technical indicators and positive earnings call further support the stock’s outlook. However, profitability challenges and valuation concerns weigh on the overall score.
To see Spark’s full report on AVDL stock, click here.
More about Avadel Pharmaceuticals
Avadel Pharmaceuticals is a biopharmaceutical company focused on transforming medicines to improve lives, particularly in the field of sleep medicine. The company is known for its innovative treatments for sleep disorders, including its product LUMRYZ, an extended-release sodium oxybate medication for narcolepsy.
Average Trading Volume: 1,377,789
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.43B
See more data about AVDL stock on TipRanks’ Stock Analysis page.